Laboratory of Clinical Proteomic Giovanni Paolo II Hospital ASL Lecce Italy

Italy

Laboratory of Clinical Proteomic Giovanni Paolo II Hospital ASL Lecce Italy

Italy
SEARCH FILTERS
Time filter
Source Type

Agostinelli C.,University of Bologna | Carloni S.,Biosciences Laboratory Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS Meldola Italy | Limarzi F.,University of Bologna | Righi S.,University of Bologna | And 10 more authors.
Histopathology | Year: 2017

Aims: Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase involved in glycogen metabolism, cell cycle progression, differentiation, embryogenesis, migration, metabolism, survival and cellular senescence. Its main biological function is to inhibit β-catenin by sequestration and promotion of its proteasomal degradation in the Wnt canonical pathway; however, GSK-3β interacts with multiple signalling pathways, and aberrant expression of the enzyme was reported in many solid neoplasms. This study aimed to investigate the biological relevance of GSK-3β in classical Hodgkin lymphomas (cHL). Methods and results: We analysed the functional status of GSK-3β enzyme in cHL by using antibodies raised against fixation-resistant epitopes of phospho Y216 GSK-3β (active form), phospho S9 GSK-3β (inactive form) and β-catenin protein. We first detected the pY216 GSK-3β active form of the enzyme in 100 of 100 (100%) of the cases, and in line with the latter expression profile, the β-catenin protein was found in only 12 of 100 (12%) of the samples. As reported previously in bladder cancer, pancreatic adenocarcinoma and chronic lymphocytic leukaemia, we showed an aberrant nuclear localization in the neoplastic clone of active pY216 GSK-3β in 78 of 100 (78%) of cHL cases. Conclusions: We demonstrated the activation of GSK-3β in cHL resulting in inhibition of the Wnt/β-catenin signal cascade and the aberrant accumulation of its activated form in nuclei of Hodgkin Reed-Sternberg and Hodgkin cells. These findings may be relevant for future clinical studies, identifying GSK-3β as a potential therapeutic target for cHL. © 2017 John Wiley & Sons Ltd.

Loading Laboratory of Clinical Proteomic Giovanni Paolo II Hospital ASL Lecce Italy collaborators
Loading Laboratory of Clinical Proteomic Giovanni Paolo II Hospital ASL Lecce Italy collaborators